ArticleFrontiers in cardiovascular medicine2026
Transcatheter closure of PDA: how the pathway changed from classical fluoroscopy approach.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patent ductus arteriosus (PDA) is a common congenital cardiac defect traditionally managed by surgical and transcatheter closure under fluoroscopic guidance. Over recent years, significant advances in imaging modalities, device technology, and procedural planning have transformed the pathway for PDA closure, reducing reliance on classical fluoroscopy-based techniques. This review outlines the evolution of transcatheter PDA closure from conventional fluoroscopic approaches to contemporary strategies incorporating echocardiographic guidance, hybrid imaging, and radiation-sparing protocols. These changes have enhanced procedural safety, reduced radiation exposure to patients and operators, shortened procedure times, and expanded eligibility to younger and higher-risk populations. Understanding this evolving pathway is essential for optimizing outcomes and guiding future practice in transcatheter PDA closure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.